News on clinical chemistry systems and applications.
Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.
The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.
They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.
Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
